Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer

JOURNAL ARTICLE published April 2019 in Thoracic Cancer

Authors: Takahiro Uchida | Kyoichi Kaira | Ou Yamaguchi | Atsuto Mouri | Ayako Shiono | Yu Miura | Kosuke Hashimoto | Fuyumi Nishihara | Yoshitake Murayama | Kunihiko Kobayashi | Hiroshi Kagamu